hero img

Results with TECARTUS

87% of patients saw a decrease in cancer (52 out of 60)

62% of patients achieved complete remission, seeing a disappearance of all signs of cancer. This does not always mean the cancer has been cured

25% of patients achieved partial remission, experiencing a decrease in the amount of cancer within the body

Pie chart displaying TECARTUS remission and partial remission results
62% (37 out of 60 patients)
25% (15 out of 60 patients)

TECARTUS can help you achieve remission
in as little as 1 month after treatment

TECARTUS was studied in patients with mantle cell lymphoma whose prior treatment either didn’t work or had stopped working. In the clinical study of 60 patients, 87% saw a decrease in cancer after being followed for ~12.3 months. Many of these patients responded to treatment in as little as 1 month (range 0.8 to 3.1 months).

TECARTUS uses your own immune system to fight mantle cell lymphoma


It starts with your own T cells

Your immune system has different types of white blood cells, all working together to keep you healthy. One type of white blood cell, called the T cell, has the very important job of finding and destroying things that can harm your body, like infection or cancer. In some cases, however, your T cells aren't able to recognize cancer cells.

T cells T cells T cells
TECARTUS CAR T cells T cells
TECARTUS CAR T cells T cells
TECARTUS CAR T cells T cells

TECARTUS helps your T cells do the job they were meant to do

TECARTUS is a therapy where your own T cells are modified in a way that can improve their ability to recognize and destroy cancer cells. TECARTUS is a type of immunotherapy known as CAR T, or Chimeric Antigen Receptor T-cell therapy.

Kite Konnect® is here to help you

For additional help finding an Authorized Treatment Center or information about the support resources that may be available to you, call Kite Konnect 1‑844‑454‑KITE [5483], Monday–Friday, 5 AM–6 PM PT.

Kite Konnect® Logo

Learn more about patient support